Ting Hua-Sieng, Chin Pui-See, Yeo George S H, Kwek Kenneth
MIS Department, Obstetrics and Gynaecology, KK Women's and Children's Hospital, Singapore.
Ann Acad Med Singap. 2007 Jun;36(6):399-402.
The objective of the study was to compare the effectiveness of bedside test kits for pIGFBP-1 and fetal fibronectin test in predicting preterm delivery.
Patients presenting with symptoms of preterm labour between 24 and 34 weeks of gestation were recruited. Both pIGFBP-1 and fetal fibronectin bedside tests were performed. Managing obstetricians and patients were blinded to the pIGFBP-1 and fetal fibronectin results. Tocolysis and steroid therapy were administered to all the recruited patients. Outcome data were collected after delivery.
One hundred and eight patients were recruited into the study. Fourteen patients had to be excluded from the final analysis due to incomplete data and failure to meet inclusion criteria. Ninety-four patients had complete data for analysis. Among those with negative pIGFBP-1 and fetal fibronectin results, the median [+/-standard deviation (SD)] gestational age at delivery was 37.4 weeks (+/-2.8 weeks) and 37.4 weeks (+/-2.1 weeks), respectively. Among those with positive pIGFBP-1 and fetal fibronectin results, the median (+/-SD) gestational age at delivery was 32.9 weeks (+/-4.0 weeks) and 34.2 weeks (+/-4.2 weeks), respectively (P <0.001 for both pIGFBP-1 and fetal fibronectin). A positive result with either test was associated with a significantly reduced admission-to-delivery interval. The median admission-to-delivery interval was 2.8 weeks shorter in the group with positive pIGFBP-1 results compared to those with a negative pIGFBP-1 result (2.3 weeks compared with 5.1 weeks) (P <0.001). This is 1.8 weeks shorter in the group with positive fibronectin results, compared to those with a negative result (3.3 weeks compared with 5.1 weeks) (P=0.002). Both pIGFBP-1 and fetal fibronectin tests have high negative predictive value (NPV) in predicting risk of delivery within 48 hours, 7, or 14 days (1.00; 0.92; 0.92 and 0.97; 0.89; 0.89, respectively).
Both pIGFBP-1 and fetal fibronectin tests are effective adjuvant bedside test kits for the prediction of preterm delivery in patients presenting with signs or symptoms of preterm labour. pIGFBP-1 has the higher NPV of 1.00 in predicting risk of delivery within 48 hours.
本研究的目的是比较用于检测胰岛素样生长因子结合蛋白-1(pIGFBP-1)的床边检测试剂盒和胎儿纤连蛋白检测在预测早产方面的有效性。
招募妊娠24至34周出现早产症状的患者。同时进行pIGFBP-1和胎儿纤连蛋白床边检测。产科管理人员和患者对pIGFBP-1和胎儿纤连蛋白检测结果不知情。对所有招募的患者进行了宫缩抑制治疗和类固醇治疗。分娩后收集结局数据。
108名患者被纳入研究。由于数据不完整和未达到纳入标准,14名患者被排除在最终分析之外。94名患者有完整数据可供分析。在pIGFBP-1和胎儿纤连蛋白检测结果为阴性的患者中,分娩时的中位胎龄(±标准差)分别为37.4周(±2.8周)和37.4周(±2.1周)。在pIGFBP-1和胎儿纤连蛋白检测结果为阳性的患者中,分娩时的中位胎龄(±标准差)分别为32.9周(±4.0周)和34.2周(±4.2周)(pIGFBP-1和胎儿纤连蛋白检测结果的P值均<0.001)。两种检测中任何一种结果为阳性均与入院至分娩间隔显著缩短相关。与pIGFBP-1检测结果为阴性的组相比,pIGFBP-1检测结果为阳性的组的中位入院至分娩间隔短2.8周(分别为2.3周和5.1周)(P<0.001)。与胎儿纤连蛋白检测结果为阴性的组相比,检测结果为阳性的组的这一间隔短1.8周(分别为3.3周和5.1周)(P = 0.002)。pIGFBP-1和胎儿纤连蛋白检测在预测48小时、7天或14天内分娩风险方面均具有较高阴性预测值(NPV)(分别为1.00;0.92;0.92和0.97;0.89;0.89)。
pIGFBP-1和胎儿纤连蛋白检测都是有效的辅助床边检测试剂盒,可用于预测出现早产体征或症状患者的早产情况。pIGFBP-1在预测48小时内分娩风险方面的NPV更高,为1.00。